{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:00:56Z","timestamp":1790395256346,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.farma.2026.07.010","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:24:54Z","timestamp":1790393094000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["[Translated article] Pharmaceutical intervention for the reduction of risks associated with medications in patients with liver cirrhosis in primary care"],"prefix":"10.1016","author":[{"given":"Andrea","family":"Rodr\u00edguez Esqu\u00edroz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaya","family":"Echeverr\u00eda Gorriti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Mar\u00edn Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorea","family":"Sanz \u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Garc\u00eda Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Gorricho Mendivil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"\u00dariz Otano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Garj\u00f3n Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"Aguinaga Ontoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"s1","key":"10.1016\/j.farma.2026.07.010_bb0005","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40261-022-01150-w","article-title":"Management of pharmacologic adverse effects in advanced liver disease","volume":"42","author":"Garc\u00eda-Cort\u00e9s","year":"2022","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.farma.2026.07.010_bb0010","first-page":"1","article-title":"Uso seguro de medicamentos en pacientes con cirrosis","volume":"31","author":"Rodr\u00edguez Esqu\u00edroz","year":"2023","journal-title":"Bol Inf Farmacoter Navarra"},{"key":"10.1016\/j.farma.2026.07.010_bb0015","author":"Barzel"},{"key":"10.1016\/j.farma.2026.07.010_bb0020","unstructured":"RxCirrhose. [accessed 14 Ene 2026]. Available from: https:\/\/www.rxcirrhose.ca\/?hl=fr."},{"issue":"5","key":"10.1016\/j.farma.2026.07.010_bb0025","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/hep4.1334","article-title":"Medication-related problems in outpatients with decompensated cirrhosis: opportunities for harm prevention","volume":"3","author":"Hayward","year":"2019","journal-title":"Hepatol Commun"},{"issue":"SEP","key":"10.1016\/j.farma.2026.07.010_bb0030","first-page":"1","article-title":"Evaluation of information in summaries of product characteristics (SMPCs) on the use of a medicine in patients with hepatic impairment","volume":"10","author":"Weersink","year":"2019","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.farma.2026.07.010_bb0035","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40261-023-01289-0","article-title":"Dose recommendations for common drugs in patients with liver cirrhosis: a systematic literature review","volume":"43","author":"Karsten Dafonte","year":"2023","journal-title":"Clin Drug Investig"},{"issue":"6","key":"10.1016\/j.farma.2026.07.010_bb0040","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2165\/00002018-200528060-00005","article-title":"Dose adjustment in patients with liver disease","volume":"28","author":"Delc\u00f2","year":"2005","journal-title":"Drug Saf"},{"issue":"10","key":"10.1016\/j.farma.2026.07.010_bb0045","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-012991","article-title":"Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion","volume":"6","author":"Weersink","year":"2016","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.farma.2026.07.010_bb0050","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/bcp.14177","article-title":"Medication safety in patients with hepatic impairment: a survey of community pharmacists' knowledge level and their practice in caring for these patients","volume":"86","author":"Weersink","year":"2020","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.farma.2026.07.010_bb0055","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1002\/hep4.1612","article-title":"Improving medication-related outcomes in chronic liver disease","volume":"4","author":"Hayward","year":"2020","journal-title":"Hepatol Commun"},{"issue":"19","key":"10.1016\/j.farma.2026.07.010_bb0060","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000032608","article-title":"Prevalence and global trends of polypharmacy in patients with chronic liver disease: a systematic review and meta-analysis","volume":"102","author":"Danjuma","year":"2023","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.farma.2026.07.010_bb0065","first-page":"A183","article-title":"Drug prescription in hepatic cirrhosis: pitfalls and room for improvement","volume":"32","author":"Rodr\u00edguez Esqu\u00edroz","year":"2025","journal-title":"Eur J Hosp Pharm"},{"issue":"7","key":"10.1016\/j.farma.2026.07.010_bb0070","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s40264-024-01417-5","article-title":"The reporting recommendations intended for pharmaceutical risk minimization evaluation studies: standards for reporting of implementation studies extension (RIMES-SE)","volume":"47","author":"Smith","year":"2024","journal-title":"Drug Saf"},{"key":"10.1016\/j.farma.2026.07.010_bb0075","unstructured":"Centro de informaci\u00f3n online de medicamentos de la Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Buscador para profesionales sanitarios. [accessed 14 Ene 2026]. Available from: https:\/\/cima.aemps.es\/cima\/publico\/buscadoravanzado.html."},{"key":"10.1016\/j.farma.2026.07.010_bb0080","unstructured":"UpToDate. [accessed 14 Ene 2026]. Available from: https:\/\/www.uptodate.com\/contents\/search."},{"issue":"1","key":"10.1016\/j.farma.2026.07.010_bb0090","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2018-000271","article-title":"Opioid and benzodiazepine prescription among patients with cirrhosis compared to other forms of chronic disease","volume":"6","author":"Konerman","year":"2019","journal-title":"BMJ Open Gastroenterol"},{"issue":"6","key":"10.1016\/j.farma.2026.07.010_bb0095","article-title":"Deprescribing zolpidem reduces falls and fractures in patients with cirrhosis","volume":"4","author":"Tapper","year":"2022","journal-title":"JHEP Rep"},{"issue":"15","key":"10.1016\/j.farma.2026.07.010_bb0100","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/ajhp\/zxad089","article-title":"Infection risk and management strategies for patients with cirrhosis taking proton pump inhibitors","volume":"80","author":"Zerr","year":"2023","journal-title":"Am J Heal Pharm"},{"issue":"1","key":"10.1016\/j.farma.2026.07.010_bb0105","doi-asserted-by":"crossref","first-page":"44","DOI":"10.5152\/tjg.2022.20689","article-title":"Correlation between proton pump inhibitors and the complications of liver cirrhosis: a systematic review and meta-analysis","volume":"33","author":"Hwang","year":"2022","journal-title":"Turk J Gastroenterol"},{"issue":"1","key":"10.1016\/j.farma.2026.07.010_bb0110","doi-asserted-by":"crossref","first-page":"203","DOI":"10.14309\/ajg.0000000000002462","article-title":"An emulated clinical trial of deprescribing proton pump inhibitors in patients with cirrhosis","volume":"119","author":"Tapper","year":"2024","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"10.1016\/j.farma.2026.07.010_bb0115","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1111\/bcp.13615","article-title":"Safe use of proton pump inhibitors in patients with cirrhosis","volume":"84","author":"Weersink","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.farma.2026.07.010_bb0120","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1016\/j.cgh.2022.08.033","article-title":"AGA Clinical practice update on the evaluation and management of acute kidney injury in patients with cirrhosis: expert review","volume":"20","author":"Flamm","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.farma.2026.07.010_bb0125","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1177\/2050640620975224","article-title":"Deprescribing medications that may increase the risk of hepatic encephalopathy: a qualitative study of patients with cirrhosis and their doctors","volume":"9","author":"Williams","year":"2021","journal-title":"United Eur Gastroenterol J"},{"issue":"8","key":"10.1016\/j.farma.2026.07.010_bb0130","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1007\/s00228-013-1502-z","article-title":"Dose adjustment in patients with liver cirrhosis: impact on adverse drug reactions and hospitalizations","volume":"69","author":"Franz","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.farma.2026.07.010_bb0135","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/hep4.1334","article-title":"Medication-related problems in outpatients with decompensated cirrhosis: opportunities for harm prevention","volume":"3","author":"Hayward","year":"2019","journal-title":"Hepatol Commun"},{"issue":"suppl 2","key":"10.1016\/j.farma.2026.07.010_bb0140","first-page":"95","article-title":"High-risk medication-related problems are prevalent in people with decompensated cirrhosis","volume":"32","author":"Hayward","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.farma.2026.07.010_bb0145","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1111\/liv.13892","article-title":"Optimizing medication management for patients with cirrhosis: evidence-based strategies and their outcomes","volume":"38","author":"Thomson","year":"2018","journal-title":"Liver Int"},{"issue":"8","key":"10.1016\/j.farma.2026.07.010_bb0150","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s00228-019-02688-z","article-title":"Medicine use and medicine-related problems in patients with liver cirrhosis: a systematic review of quantitative and qualitative studies","volume":"75","author":"Cheema","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.farma.2026.07.010_bb0085","article-title":"Study protocol: evaluation of a pharmaceutical intervention for safe use of medications in patients with liver cirrhosis","volume":"100","author":"Rodr\u00edguez Esqu\u00edroz","year":"2026","journal-title":"Rev Esp Salud Publica"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634326001790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634326001790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:25:01Z","timestamp":1790393101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634326001790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":30,"alternative-id":["S1130634326001790"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2026.07.010","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] Pharmaceutical intervention for the reduction of risks associated with medications in patients with liver cirrhosis in primary care","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2026.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2026.04.012","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}